Potassium Amoxicillin Clavulanate Oral Suspension (2023)


Oral suspension for veterinary use
for dogs and cats

Federal law (USA) restricts the use of this drug by or on the order of a licensed veterinarian.

Amoxicillin Clavulanate Potassium Oral Suspension is an oral preparation consisting of the broad-spectrum antibiotic amoxicillin trihydrate and the beta-lactamase inhibitor clavulanate potassium (the potassium salt of clavulanic acid).

Amoxicillin trihydrate is a semi-synthetic antibiotic with broad-spectrum bactericidal activity against many Gram-positive and Gram-negative, aerobic and anaerobic microorganisms. Not resistant to destruction by β-lactamase; therefore it is not effective against β-lactamase-producing bacteria. Chemically, it is D(-)-α-amino-p-hydroxybenzylpenicillin trihydrate.

Clavulanic acid is an inhibitor of beta-lactamase produced by fermentationStreptomyces clavulus. Clavulanic acid itself has only weak antibacterial activity. Chemically, potassium clavulanate is potassium z-(3R,5R)-2-β-hydroxyethylidene clavim-3-carboxylate.

Amoxicillin and Clavulanate Potassium Oral Suspension is stable in the presence of gastric acid and is not significantly affected by gastric or intestinal contents. The two components are rapidly absorbed resulting in serum, urine and tissue concentrations of amoxicillin and clavulanic acid similar to those produced when administered alone.

Amoxicillin and clavulanate readily diffuse into most body tissues and fluids, with the exception of the brain and spinal fluid, where amoxicillin can penetrate adequately when the meninges are inflamed. Most of amoxicillin is excreted unchanged in the urine. The penetration of clavulanic acid into the spinal fluid is currently unknown. Approximately 15% of the administered dose of clavulanic acid is excreted in the urine within the first 6 hours.

Amoxicillin Clavulanate Potassium Oral Suspension combines the unique characteristics of broad-spectrum antibiotics and β-lactamase inhibitors, effectively expanding the antibacterial spectrum of amoxicillin, including producing β-lactamase and not producing β-lactamase. anaerobic organisms.


Amoxicillin is bactericidal and inhibits the biosynthesis of cell wall mucopeptides in sensitive organisms. The action of clavulanic acid extends the antimicrobial spectrum of amoxicillin to include microorganisms resistant to amoxicillin and other β-lactam antibiotics.

Amoxicillin/clavulanic acid has been shown to be active against a wide range of β-lactamase-producing Gram-positive and Gram-negative aerobic, facultative and obligate anaerobic strains. Many strains of the following organisms have been shown to be susceptible to amoxicillin/clavulanic acid, including β-lactamase-producing strains isolated from veterinary sourcesin vitroBut the clinical significance of this activity has not yet been demonstrated in animals. Aerobic bacteria, inclusiveStaphylococcus aureus1, producing β-lactamaseStaphylococcus aureus1(penicillineresistentie),staphylococcikind1,Staphylococcus epidermidis,Staphylococcus intermedia,Streptococcus faecalis,streptococcikind1,Corynebacterium pyogenes,Corynebacteriumkind,Erysipelothrix rhusiopathiae,Bordetella bronchiseptica,Escherichia coli1,Protus is great,Proteuskind,Enterobacterkind,Klebsiella pneumoniae,Salmonella Dublin,Salmonella typhimurium,Pasteurella multocida1,Pasteurella hemolyticus,Pasteurellakind1

Aerobic and anaerobic flora isolated from gingival cultures of dogs with clinical evidence of periodontal disease. Both Gram-positive and Gram-negative aerobic and anaerobic subgingival isolates showed susceptibility to amoxicillin/clavulanic acid when tested for antimicrobial susceptibility.

The sensitivity of these organisms has also beenlivestudy.

drug allergy testing:

Recommended method for quantifying disc sensitivity (FEDERAL REGISTER 37:20527-29; Bauer AW, Kirby WMM, Sherris JC,et al.:Antibiotic susceptibility testing was performed using the standardized single-pan method.American Journal of Clinical Pathways45:493, 1966) Evaluation of bacterial susceptibility to amoxicillin and clavulanic acid potassium tablets and oral suspension using 30 mcg Augmentin® (AMC) discs.

Amoxicillin Clavulanate Potassium Oral Suspension Drops is indicated for the treatment of:

pup:Skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma caused by susceptible strains of: β-lactamase producingStaphylococcus aureus,Does not produce beta-lactamasesStaphylococcus aureus,staphylococcifriendly,streptococcitypes, andEscherichia coli

Periodontal infections caused by susceptible strains of aerobic and anaerobic bacteria. Amoxicillin-clavulanic acid oral suspension has been shown to be clinically effective in the treatment of periodontal disease in dogs.

Kat:Skin and soft tissue infections, such as wounds, abscesses and cellulitis/dermatitis, caused by susceptible strains of microorganisms that: produce beta-lactamaseStaphylococcus aureus, does not produce β-lactamaseStaphylococcus aureus,staphylococcifriendly,streptococcifriendly,Escherichia coli,Pasteurella multocida, InPasteurellafriendly.

Urinary tract infection (cystitis) caused by susceptible strainsEscherichia coli

Treatment with amoxicillin and potassium clavulanate oral suspension can be initiated until the results of bacteriological and susceptibility studies are available.

Cultures should be performed prior to treatment to determine the susceptibility of microorganisms to oral amoxicillin and clavulanate potassium suspension. Treatment may be reassessed after sensitivity results and clinical response to drugs have been established.

This drug is contraindicated in animals with a history of hypersensitivity reactions to penicillin or cephalosporin.

Safety for use in pregnant or breeding animals has not been established. Only for dogs and cats.

Amoxicillin Clavulanate Potassium Oral Suspension contains a semi-synthetic penicillin (amoxicillin) which may cause an allergic reaction.

In case of an allergic reaction, take epinephrine and/or steroids.

To report a suspected adverse drug reaction, seek technical assistance, or obtain a copy of a safety data sheet, contact Dechra Veterinary Products at (866) 933-2472.

For more information on reporting adverse reactions to veterinary drug products, contact the FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae

pup:The recommended dose is 6.25 mg/lb (1 ml/10 lbs) of body weight twice daily. Skin and soft tissue infections such as abscesses, cellulitis, wounds, superficial/juvenile pyoderma and periodontal infections should be treated 5-7 days or 48 hours after all symptoms have resolved. If no response is observed after 5 days of treatment, treatment should be discontinued and the case reassessed. Deep pyoderma may require 21 days of treatment; the maximum duration of treatment should not exceed 30 days.

Kat:The recommended dose is 62.5 mg (1 ml) twice a day. Skin and soft tissue infections, such as abscesses and cellulitis/dermatitis, should be treated for 5-7 days or 48 hours after resolution of all symptoms, up to a maximum of 30 days. If no response is observed after 3 days of treatment, treatment should be discontinued and the case reassessed.

Urinary tract infections may require treatment for 10 to 14 days or longer. The maximum duration of treatment should not exceed 30 days.

Reconstitution Instructions - Oral Suspension:

Add 14ml of water to the 22ml bottle and shake vigorously. To administer a dose, push the plastic adapter into the neck of the bottle, insert the dosing syringe into the adapter, invert the bottle and slowly pull back on the plunger to deliver the prescribed dose. The caps fit on plastic adapters for easy storage. Each milliliter of the suspension contains 50 mg of active amoxicillin as the trihydrate and 12.5 mg of active clavulanic acid as the potassium salt.


Any unused portion of the reconstituted suspension should be discarded after 10 days. Refrigeration of the reconstituted suspension is required. Shake well before use.

Store dry powder at controlled room temperature (20-25°C).

Amoxicillin and Potassium Clavulanate drops for oral suspension in drops are supplied in a 22 ml vial containing 50 mg amoxicillin/12.5 mg clavulanic acid per ml.

Approved by FDA, ANADA # 200-604

Augmentin is a trademark of GlaxoSmithKline, LLC.

Manufactured for:
Dekla Veterinary Products
7015 College Avenue, Suite 525
Overland Park, KS 66211 United States

Made in Austria.

Revised November 2020



Amoxicillin and clavulanic acid
Potassium For Oral Suspension


Oral suspension for veterinary use
for dogs and cats

After reconstitution, each ml
50 mg amoxicillinetrihydraat
and 12.5 mg clavulanic acid ash
Potassium salt.

Do not use if the product is discolored

NOTE: Federal (US) law restricts this
Drugs used by or on behalf of a person
A licensed veterinarian.

Approved by FDA, ANADA # 200-604

15 ml


Potassium Amoxicillin Clavulanate Oral Suspension (1)


Top Articles
Latest Posts
Article information

Author: Aron Pacocha

Last Updated: 10/05/2023

Views: 6165

Rating: 4.8 / 5 (68 voted)

Reviews: 83% of readers found this page helpful

Author information

Name: Aron Pacocha

Birthday: 1999-08-12

Address: 3808 Moen Corner, Gorczanyport, FL 67364-2074

Phone: +393457723392

Job: Retail Consultant

Hobby: Jewelry making, Cooking, Gaming, Reading, Juggling, Cabaret, Origami

Introduction: My name is Aron Pacocha, I am a happy, tasty, innocent, proud, talented, courageous, magnificent person who loves writing and wants to share my knowledge and understanding with you.